{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:22:17Z","timestamp":1793190137027,"version":"4.5.0"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.eclinm.2024.103050","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T08:06:50Z","timestamp":1736323610000},"page":"103050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Roads to remission: evolving treatment concepts in type 2 inflammatory diseases"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9305-9348","authenticated-orcid":false,"given":"Marek","family":"Lommatzsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Blumchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bousquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy G.","family":"Brusselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wytske J.","family":"Fokkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckard","family":"Hamelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagen","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Pfaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh A.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Taube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo H.","family":"Tarner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wagenmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Werfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margitta","family":"Worm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Renz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.eclinm.2024.103050_bib1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41573-023-00750-1","article-title":"Type 2 chronic inflammatory diseases: targets, therapies and unmet needs","volume":"22","author":"Kolkhir","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"10335","key":"10.1016\/j.eclinm.2024.103050_bib2","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(22)00331-2","article-title":"Disease-modifying anti-asthmatic drugs","volume":"399","author":"Lommatzsch","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2024.103050_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/all.16382","article-title":"Biologics and airway remodeling in asthma: early, late, and potential preventive effects","author":"Varricchi","year":"2025","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.eclinm.2024.103050_bib4","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41573-023-00735-0","article-title":"Disease modification in inflammatory skin disorders: opportunities and challenges","volume":"22","author":"Bieber","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.eclinm.2024.103050_bib5","first-page":"287","article-title":"EPOS2020\/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP","volume":"62","author":"Fokkens","year":"2024","journal-title":"Rhinology"},{"issue":"11","key":"10.1016\/j.eclinm.2024.103050_bib6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41577-021-00538-7","article-title":"Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions?","volume":"21","author":"Akdis","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.eclinm.2024.103050_bib7","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nm.3300","article-title":"Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma","volume":"19","author":"Brusselle","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.eclinm.2024.103050_bib8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri3632","article-title":"The production and regulation of IgE by the immune system","volume":"14","author":"Wu","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/thoraxjnl-2013-203738","article-title":"Against all odds: anti-IgE for intrinsic asthma?","volume":"69","author":"Lommatzsch","year":"2014","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.eclinm.2024.103050_bib10","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The cytokines of asthma","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.eclinm.2024.103050_bib11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis - common origins, divergent mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"10427","key":"10.1016\/j.eclinm.2024.103050_bib12","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(23)01736-1","article-title":"Diagnosis and management of ANCA-associated vasculitis","volume":"403","author":"Kronbichler","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.eclinm.2024.103050_bib13","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1053\/j.gastro.2020.10.065","article-title":"Selecting end points for disease-modification trials in inflammatory bowel disease: the SPIRIT consensus from the IOIBD","volume":"160","author":"Le Berre","year":"2021","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.eclinm.2024.103050_bib14","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2665-9913(24)00162-0","article-title":"Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials","volume":"6","author":"Parodis","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"6055","key":"10.1016\/j.eclinm.2024.103050_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bmj.1.6055.195","article-title":"Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes","volume":"1","author":"Amos","year":"1977","journal-title":"Br Med J"},{"issue":"6","key":"10.1016\/j.eclinm.2024.103050_bib16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.eclinm.2024.103050_bib18","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2024.103050_bib19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A\u00a0simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.eclinm.2024.103050_bib20","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.eclinm.2024.103050_bib21","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.21235","article-title":"Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states","volume":"52","author":"Aletaha","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"5 Suppl 39","key":"10.1016\/j.eclinm.2024.103050_bib22","first-page":"S100","article-title":"The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.103050_bib23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/ard.2006.054205","article-title":"Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values","volume":"66","author":"Inoue","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"9430","key":"10.1016\/j.eclinm.2024.103050_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eclinm.2024.103050_bib25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/med.2610050305","article-title":"Disease-modifying antirheumatic drugs","volume":"5","author":"Stecher","year":"1985","journal-title":"Med Res Rev"},{"issue":"10","key":"10.1016\/j.eclinm.2024.103050_bib26","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/art.1780241012","article-title":"Preliminary criteria for clinical remission in rheumatoid arthritis","volume":"24","author":"Pinals","year":"1981","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.42347","article-title":"American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision","volume":"75","author":"Studenic","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.103050_bib28","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/ard.2003.010298","article-title":"Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis","volume":"63","author":"van Aken","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.eclinm.2024.103050_bib29","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.eclinm.2024.103050_bib30","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1007\/s10067-022-06307-8","article-title":"Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis","volume":"41","author":"Khader","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.eclinm.2024.103050_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h1389","article-title":"Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial","volume":"350","author":"van Herwaarden","year":"2015","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.eclinm.2024.103050_bib32","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.22943","article-title":"Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients","volume":"56","author":"Aletaha","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-020-00785-1","article-title":"Asthma epidemiology and risk factors","volume":"42","author":"Stern","year":"2020","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.eclinm.2024.103050_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106658","article-title":"Pediatric obesity and severe asthma: targeting pathways driving inflammation","volume":"188","author":"Di Cicco","year":"2023","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.eclinm.2024.103050_bib35","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2213-2600(21)00023-0","article-title":"Neutrophilic asthma: misconception or misnomer?","volume":"9","author":"Nair","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.eclinm.2024.103050_bib36","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1111\/all.14997","article-title":"Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma","volume":"76","author":"Lommatzsch","year":"2021","journal-title":"Allergy"},{"issue":"7","key":"10.1016\/j.eclinm.2024.103050_bib37","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.jaip.2022.03.019","article-title":"Characterization of asthma by age of onset: a multi-database cohort study","volume":"10","author":"Baan","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib38","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1183\/09031936.00138707","article-title":"Global strategy for asthma management and prevention: GINA executive summary","volume":"31","author":"Bateman","year":"2008","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.eclinm.2024.103050_bib39","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","article-title":"Development and validation of a questionnaire to measure asthma control","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: a survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.103050_bib41","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jaci.2012.08.023","article-title":"The asthma control test and asthma control questionnaire for assessing asthma control: systematic review and meta-analysis","volume":"131","author":"Jia","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib42","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02730-2021","article-title":"Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes","volume":"59","author":"Reddel","year":"2022","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000247298","article-title":"Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European task force on atopic dermatitis","volume":"186","year":"1993","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.eclinm.2024.103050_bib44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(23)00415-0","article-title":"Pioneering a paradigm shift in asthma management: remission as a treatment goal","volume":"12","author":"Lommatzsch","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.eclinm.2024.103050_bib45","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.200401-033OC","article-title":"Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study","volume":"170","author":"Bateman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.eclinm.2024.103050_bib46","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2213-2600(22)00490-8","article-title":"A(2)BCD: a concise guide for asthma management","volume":"11","author":"Lommatzsch","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.eclinm.2024.103050_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(24)00304-7","article-title":"Asthma remission: a call for a globally standardised definition","author":"Lommatzsch","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.eclinm.2024.103050_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(24)00293-5","article-title":"Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis","author":"Shackleford","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.eclinm.2024.103050_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.eclinm.2024.103050_bib50","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12325-022-02098-1","article-title":"Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with benralizumab","volume":"39","author":"Menzies-Gow","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.eclinm.2024.103050_bib51","article-title":"Dupilumab induces long-term on-treatment clinical remission in patients with type 2 asthma","author":"Pavord","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib52","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12931-024-02812-3","article-title":"Barriers to clinical remission in severe asthma","volume":"25","author":"Farinha","year":"2024","journal-title":"Respir Res"},{"issue":"7","key":"10.1016\/j.eclinm.2024.103050_bib53","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults","volume":"210","author":"Perez-de-Llano","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"10423","key":"10.1016\/j.eclinm.2024.103050_bib54","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.eclinm.2024.103050_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100703","article-title":"Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma","volume":"15","author":"B\u00f6lke","year":"2022","journal-title":"World Allergy Organ J"},{"issue":"3","key":"10.1016\/j.eclinm.2024.103050_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12130","article-title":"Worldwide prevalence of rhinitis in adults: a review of definitions and temporal evolution","volume":"12","author":"Savour\u00e9","year":"2022","journal-title":"Clin Transl Allergy"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41572-020-00227-0","article-title":"Allergic rhinitis","volume":"6","author":"Bousquet","year":"2020","journal-title":"Nat Rev Dis Prim"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib58","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1465-9921-10-52","article-title":"Control of allergic rhinitis and asthma test--a formal approach to the development of a measuring tool","volume":"10","author":"Nogueira-Silva","year":"2009","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.eclinm.2024.103050_bib59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/11318410-000000000-00000","article-title":"Qualitative development of the rhinitis control assessment test (RCAT), an instrument for evaluating rhinitis symptom control","volume":"3","author":"Nathan","year":"2010","journal-title":"Patient"},{"issue":"6","key":"10.1016\/j.eclinm.2024.103050_bib60","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1365-2222.2011.03734.x","article-title":"Validation of a self-questionnaire for assessing the control of allergic rhinitis","volume":"41","author":"Demoly","year":"2011","journal-title":"Clin Exp Allergy"},{"issue":"7","key":"10.1016\/j.eclinm.2024.103050_bib61","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/all.12383","article-title":"Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper","volume":"69","author":"Pfaar","year":"2014","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.eclinm.2024.103050_bib62","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/cea.12121","article-title":"Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis","volume":"43","author":"Demoly","year":"2013","journal-title":"Clin Exp Allergy"},{"issue":"8","key":"10.1016\/j.eclinm.2024.103050_bib63","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1111\/all.16135","article-title":"Digitally-enabled, person-centred care (PCC) in allergen immunotherapy: an ARIA-EAACI Position Paper","volume":"79","author":"Pfaar","year":"2024","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.eclinm.2024.103050_bib64","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41577-022-00786-1","article-title":"Allergen immunotherapy: past, present and future","volume":"23","author":"Durham","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"10.1016\/j.eclinm.2024.103050_bib65","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1016\/j.jaip.2021.06.060","article-title":"Disease-modifying effect of Japanese cedar pollen sublingual immunotherapy tablets","volume":"9","author":"Yonekura","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.eclinm.2024.103050_bib66","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2500\/aap.2022.43.220026","article-title":"Long-term efficacy of the sublingual and subcutaneous routes in allergen immunotherapy","volume":"43","author":"Penagos","year":"2022","journal-title":"Allergy Asthma Proc"},{"issue":"8","key":"10.1016\/j.eclinm.2024.103050_bib68","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/all.13138","article-title":"Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper","volume":"72","author":"Shamji","year":"2017","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib69","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMcp1800215","article-title":"Chronic rhinosinusitis with nasal polyps","volume":"381","author":"Hopkins","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2024.103050_bib70","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/alr.22487","article-title":"Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors","volume":"10","author":"Loftus","year":"2020","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib71","first-page":"39","article-title":"Measuring control of disease in chronic rhinosinusitis; assessing the correlation between SinoNasal outcome test-22 and visual analogue scale item scores","volume":"61","author":"Dietz de Loos","year":"2023","journal-title":"Rhinology"},{"issue":"5","key":"10.1016\/j.eclinm.2024.103050_bib72","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item sinonasal outcome test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin Otolaryngol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib73","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.eclinm.2024.103050_bib74","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/all.15982","article-title":"EUFOREA\/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care","volume":"79","author":"Hellings","year":"2024","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.eclinm.2024.103050_bib75","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1016\/j.jaip.2023.04.054","article-title":"The management of chronic rhinosinusitis with nasal polyps (CRSwNP) with biologics","volume":"11","author":"Wautlet","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.eclinm.2024.103050_bib76","first-page":"194","article-title":"EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"issue":"10","key":"10.1016\/j.eclinm.2024.103050_bib77","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1111\/all.15772","article-title":"Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational Phase IV real-life study (DUPIREAL)","volume":"78","author":"De Corso","year":"2023","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.eclinm.2024.103050_bib78","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/all.15796","article-title":"Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months","volume":"78","author":"van der Lans","year":"2023","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.eclinm.2024.103050_bib79","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/all.15074","article-title":"Endotypes of chronic rhinosinusitis: relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches","volume":"77","author":"Kato","year":"2022","journal-title":"Allergy"},{"issue":"10023","key":"10.1016\/j.eclinm.2024.103050_bib80","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eclinm.2024.103050_bib81","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jaci.2023.01.001","article-title":"Might biologics serve to interrupt the atopic march?","volume":"151","author":"Spergel","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.eclinm.2024.103050_bib82","article-title":"Overview of atopic dermatitis in different ethnic groups","volume":"12","author":"Chiricozzi","year":"2023","journal-title":"J\u00a0Clin Med"},{"issue":"8","key":"10.1016\/j.eclinm.2024.103050_bib83","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1164\/rccm.202110-2418OC","article-title":"Evolution of eczema, wheeze, and rhinitis from infancy to early adulthood: four birth cohort studies","volume":"206","author":"Haider","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.eclinm.2024.103050_bib84","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/bjd.13662","article-title":"What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study","volume":"172","author":"Leshem","year":"2015","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.103050_bib85","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jaad.2020.04.104","article-title":"The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis","volume":"83","author":"Simpson","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.103050_bib86","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/bjd\/ljae017","article-title":"The construct validity, responsiveness, reliability and interpretability of the Recap of atopic eczema questionnaire (RECAP) in children","volume":"190","author":"Ragamin","year":"2024","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.103050_bib87","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaad.2024.04.026","article-title":"Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay registry","volume":"9","author":"Zhang","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.eclinm.2024.103050_bib88","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jaci.2023.05.026","article-title":"Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment","volume":"152","author":"Simpson","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.103050_bib89","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.103050_bib90","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jaci.2023.08.024","article-title":"Dupilumab strengthens herpes simplex virus type 1-specific immune responses in atopic dermatitis","volume":"152","author":"Traidl","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.103050_bib91","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaci.2022.08.026","article-title":"Attenuating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events","volume":"151","author":"Geba","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.eclinm.2024.103050_bib92","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jaci.2004.01.778","article-title":"The natural course of atopic dermatitis from birth to age 7 years and the association with asthma","volume":"113","author":"Illi","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib93","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40257-023-00827-y","article-title":"Treat-to-Target in atopic dermatitis","volume":"25","author":"Vestergaard","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.103050_bib94","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-1235","article-title":"The public health impact of parent-reported childhood food allergies in the United States","volume":"142","author":"Gupta","year":"2018","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib95","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.5630","article-title":"Prevalence and severity of food allergies among US adults","volume":"2","author":"Gupta","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.eclinm.2024.103050_bib96","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1111\/all.14290","article-title":"Frequency of food allergy in school-aged children in eight European countries-The EuroPrevall-iFAAM birth cohort","volume":"75","author":"Grabenhenrich","year":"2020","journal-title":"Allergy"},{"issue":"21","key":"10.1016\/j.eclinm.2024.103050_bib97","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa1812856","article-title":"AR101 oral immunotherapy for peanut allergy","volume":"379","author":"Vickery","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.eclinm.2024.103050_bib98","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.103050_bib99","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13601-015-0055-x","article-title":"Accidental exposures to peanut in a large cohort of Canadian children with peanut allergy","volume":"5","author":"Cherkaoui","year":"2015","journal-title":"Clin Transl Allergy"},{"issue":"4","key":"10.1016\/j.eclinm.2024.103050_bib100","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/all.13319","article-title":"EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy","volume":"73","author":"Pajno","year":"2018","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.eclinm.2024.103050_bib101","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jaci.2019.06.038","article-title":"Effect of sleep deprivation and exercise on reaction threshold in adults with peanut allergy: a randomized controlled study","volume":"144","author":"Dua","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.103050_bib102","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaci.2022.04.008","article-title":"The natural history of peanut and egg allergy in children up to age 6 years in the HealthNuts population-based longitudinal study","volume":"150","author":"Peters","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10187","key":"10.1016\/j.eclinm.2024.103050_bib103","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(19)30420-9","article-title":"Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety","volume":"393","author":"Chu","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eclinm.2024.103050_bib104","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S2352-4642(22)00006-2","article-title":"Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial","volume":"6","author":"Loke","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"10207","key":"10.1016\/j.eclinm.2024.103050_bib105","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(19)31793-3","article-title":"Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study","volume":"394","author":"Chinthrajah","year":"2019","journal-title":"Lancet"},{"issue":"10322","key":"10.1016\/j.eclinm.2024.103050_bib106","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(21)02390-4","article-title":"Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study","volume":"399","author":"Jones","year":"2022","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.eclinm.2024.103050_bib107","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1056\/NEJMoa2212895","article-title":"Phase 3 trial of epicutaneous immunotherapy in toddlers with peanut allergy","volume":"388","author":"Greenhawt","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib108","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2023.08.032","article-title":"Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: a randomized, placebo-controlled trial","volume":"153","author":"Kim","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib109","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ueg2.12465","article-title":"Incidence and prevalence of eosinophilic oesophagitis across Europe: a systematic review and meta-analysis","volume":"12","author":"Roberts","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.eclinm.2024.103050_bib110","article-title":"Prevalence and costs of eosinophilic esophagitis in the United States","author":"Thel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.103050_bib111","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.iac.2021.07.011","article-title":"Eosinophilic esophagitis","volume":"41","author":"Lehman","year":"2021","journal-title":"Immunol Allergy Clin North Am"},{"issue":"25","key":"10.1016\/j.eclinm.2024.103050_bib112","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.eclinm.2024.103050_bib113","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa2312282","article-title":"Dupilumab for eosinophilic esophagitis in patients 1 to 11 Years of age","volume":"390","author":"Chehade","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.gastro.2023.09.004","article-title":"Ascending to new heights for novel therapeutics for eosinophilic esophagitis","volume":"166","author":"Hirano","year":"2024","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.eclinm.2024.103050_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100695","article-title":"Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma","volume":"15","author":"Hanania","year":"2022","journal-title":"World Allergy Organ J"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib116","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2024.09.039","article-title":"The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study","volume":"92","author":"Paller","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.eclinm.2024.103050_bib117","article-title":"An international consensus on the use of asthma biologics in pregnancy","author":"Naftel","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.eclinm.2024.103050_bib118","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.jaip.2020.03.024","article-title":"HIV-infected patient with severe asthma treated with mepolizumab: case report","volume":"8","author":"Curto","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.eclinm.2024.103050_bib119","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1111\/all.15379","article-title":"Safety of combining biologics in severe asthma: asthma-related and unrelated combinations","volume":"77","author":"Lommatzsch","year":"2022","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.eclinm.2024.103050_bib120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/annrheumdis-2014-206696","volume":"75","author":"Fautrel","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024006291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024006291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T19:56:56Z","timestamp":1740859016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024006291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":119,"alternative-id":["S2589537024006291"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.103050","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Roads to remission: evolving treatment concepts in type 2 inflammatory diseases","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.103050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103050"}}